Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections

被引:27
作者
Akova, M
Ozcebe, O
Gullu, I
Unal, S
Gur, D
Akalin, S
Tokgozoglu, M
Telatar, F
Akalin, HE
机构
[1] Department of Medicine, Section of Infectious Diseases, Hacettepe University School of Medicine, Ankara
[2] Section of Endocrinology, Hacettepe University, School of Medicine, Ankara
[3] Department of Orthopedics, Hacettepe University, School of Medicine, Ankara
[4] Hacetttepe University School of Medicine, Department of Medicine, Section of Infectious Diseases
关键词
diabetic foot; diabetes mellitus; sulbactam-ampicillin; osteomyelitis;
D O I
10.1179/joc.1996.8.4.284
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Diabetic foot infections, a frequent and serious cause of morbidity in patients with diabetes mellitus, are caused by anaerobic and aerobic bacteria Given the fact that seriously impaired host defense factors are almost always present in these patients, bactericidal agents with a broad spectrum of antimicrobial activity are required for their treatment. Seventy-four patients with diabetic foot infections were treated with parenteral sulbactam-ampicillin (1.5%, q.i.d.). Ah patients were followed-up prospectively in order to determine the efficacy and safety of sulbctam-ampicillin. The mean duration (+/-SD) of treatment in patients with osteomyelitis (n=49) and soft tissue infections (n=25) was 41+/-5 and 14+/-3 days, respectively. Infected limbs were amputated at various levels in 14 patients (19%). Clinical cure rates were 86% and 100% in patients with osteomyelitis and with soft tissue infection, respectively. The most frequent side effect was diarrhea and observed in 10 patients (14%). The results of the present study indicate that sulbactam-ampicillin is safe and effective in the treatment of diabetic foot infections.
引用
收藏
页码:284 / 289
页数:6
相关论文
共 18 条
[1]  
AKOVA M, 1993, J CHEMOTHERAPY, V5, P181
[2]   OSTEOMYELITIS IN THE FEET OF DIABETIC-PATIENTS - LONG-TERM RESULTS, PROGNOSTIC FACTORS, AND THE ROLE OF ANTIMICROBIAL AND SURGICAL THERAPY [J].
BAMBERGER, DM ;
DAUS, GP ;
GERDING, DN .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (04) :653-660
[3]   PERSISTENCE OF POLYMICROBIAL ABSCESSES IN THE POORLY CONTROLLED DIABETIC HOST [J].
BESSMAN, AN ;
SAPICO, FL ;
TABATABAI, M ;
MONTGOMERIE, JZ .
DIABETES, 1986, 35 (04) :448-453
[4]  
Bush L M, 1989, Infect Dis Clin North Am, V3, P571
[5]  
BYBEE JD, 1964, J LAB CLIN MED, V64, P1
[6]   ASSESSMENT AND MANAGEMENT OF FOOT DISEASE IN PATIENTS WITH DIABETES [J].
CAPUTO, GM ;
CAVANAGH, PR ;
ULBRECHT, JS ;
GIBBONS, GW ;
KARCHMER, AW .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (13) :854-860
[7]  
GIBBONS GW, 1984, MANAGEMENT DIABETIC, P97
[8]  
Gilbert D N, 1989, Infect Dis Clin North Am, V3, P517
[9]   THE CLINICAL USEFULNESS OF C-REACTIVE PROTEIN MEASUREMENTS [J].
GOZZARD, DI ;
YIN, JAL ;
DELAMORE, IW .
BRITISH JOURNAL OF HAEMATOLOGY, 1986, 63 (03) :411-414
[10]   USE OF AMPICILLIN/SULBACTAM VERSUS IMIPENEM/CILASTATIN IN THE TREATMENT OF LIMB-THREATENING FOOT INFECTIONS IN DIABETIC-PATIENTS [J].
GRAYSON, ML ;
GIBBONS, GW ;
HABERSHAW, GM ;
FREEMAN, DV ;
POMPOSELLI, FB ;
ROSENBLUM, BI ;
LEVIN, E ;
KARCHMER, AW .
CLINICAL INFECTIOUS DISEASES, 1994, 18 (05) :683-693